Physician profile
Bao T Bui
NPI 1801099593
$430,431.07
in general payments reported to CMS, 2019-2025
36 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,355 · 2020: $9,327 · 2021: $38K · 2022: $92K · 2023: $134K · 2024: $75K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $249K · Travel and Lodging: $30K · Food and Beverage: $8,946 · Consulting Fee: $1,341 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $248,814.31 |
| Travel and Lodging | $30,246.86 |
| Food and Beverage | $8,946.04 |
| Consulting Fee | $1,341.00 |
| Education | $120.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112,953.16 | 2021-2025 | Ozempic |
| Merck Sharp & Dohme LLC | $107,173.08 | 2021-2025 | Verquvo, Capvaxive, Januvia |
| Janssen Pharmaceuticals, INC | $66,152.35 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55,356.96 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $50,020.59 | 2020-2025 | Jardiance, Taltz, Emgality |
| Astrazeneca Pharmaceuticals LP | $29,365.49 | 2019-2025 | Farxiga, Brilinta, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $1,918.98 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,421.86 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $697.10 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $666.55 | 2019-2025 | Camzyos, Sotyktu, Eliquis |
| Biotronik INC. | $563.21 | 2019-2021 | |
| Ucb, INC. | $460.01 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $416.29 | 2020-2023 | Xarelto |
| Shockwave Medical, INC | $396.32 | 2019-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $379.04 | 2021-2025 | Repatha, Repatha |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $294.23 | 2019-2023 | |
| Incyte Corporation | $243.02 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.37 | 2021-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $186.75 | 2023 | Inpefa |
| Almirall LLC | $171.74 | 2019-2020 | |
| Venclose INC. | $149.85 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $140.95 | 2019-2022 | |
| Celgene Corporation | $138.61 | 2019 | |
| Abiomed | $116.30 | 2019 | |
| Abbott Laboratories | $112.31 | 2023 | 2nd Gen Centrimag Primary Console |
| Genzyme Corporation | $93.55 | 2023 | |
| Amarin Pharma, INC. | $86.51 | 2021 | |
| Cardiovascular Systems INC. | $82.30 | 2022 | |
| Leo Pharma INC. | $81.57 | 2019-2020 | |
| Scpharmaceuticals INC. | $79.34 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $75.76 | 2019-2024 | |
| Philips North America LLC | $54.62 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Dermira, INC. | $49.95 | 2019 | |
| Boston Scientific Corporation | $39.81 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $38.15 | 2024 | Uptravi, Opsumit |
| Kestra Medical Technology Services, INC. | $22.39 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bao Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.